Gilead Sciences | GILD - Pre Tax Profit


Gilead Sciences reported $-7.53B in Pre-Tax Profit for its fiscal quarter ending in June of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Amgen USD 2.08B 570M Mar/2026
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.85B 583.8M Mar/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Incyte USD 751.51M 407.91M Jun/2026
J&J USD 8.66B 839M Jun/2026
Merck USD -3.53B 6.95B Mar/2026
Moderna USD -1.33B 535M Mar/2026
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR 837M 1.17B Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026